Ticker LaunchReverse merger · Completed · CARM
Carisma Therapeutics Inc.
Reverse merger with Sesen Bio, Inc.
Carisma Therapeutics Inc. merged into Sesen Bio, Inc., a Nasdaq-listed biotech that sold its lead program assets and wound down, in a reverse merger that takes the private company public. The deal was announced on Sep 20, 2022 and closed on Mar 7, 2023. The combined company trades as Carisma Therapeutics Inc. (CARM) on Nasdaq.
Carisma Therapeutics is a clinical-stage biopharmaceutical company developing CAR-M engineered macrophage immunotherapies for cancer, led by CT-0508, with a collaboration with Moderna on in vivo CAR-M therapeutics. It became public by merging with Sesen Bio.
- Status
- Completed
- Private company
- Carisma Therapeutics Inc.
- Public company
- Sesen Bio, Inc.
- Public company business before
- Nasdaq-listed biotech that sold its lead program assets and wound down
- Announced
- Sep 20, 2022
- Closed
- Mar 7, 2023
- Combined company
- Carisma Therapeutics Inc. (CARM)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Contingent value rights (CVR)
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Form 8-K (completion of acquisition) Mar 8, 2023
- Press release (Exhibit 99)
- All filings on EDGAR CIK 1485003
Other completed reverse mergers
- CalciMedica, Inc.into Graybug Vision, Inc. · Mar 22, 2023
- Best Labs, Inc.into Nowtransit Inc · Mar 10, 2023
- Bret Consultores, SAPI de CV: Carbon Captureinto Arma Services Inc · Feb 27, 2023
- Enliven Inc. (Former Enliven)into IMARA Inc. · Feb 23, 2023
- Cycle Energy Corp.into American International Holdings Corp. · Feb 15, 2023
- Lithium Harvest ApSinto Sustainable Projects Group Inc. · Feb 15, 2023